Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med 2020;382:6 de febrero. [Ref.ID 103518]

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]

Rao K, Young VB, Malani PN. Capsules for fecal microbiota transplantation in recurrent Clostridium difficile infection. The new way forward or a tough pill to swallow?. JAMA 2017;318:1979-80. [Ref.ID 102172]

Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection?. Lancet 2017;390:107-9. [Ref.ID 101668]

Anónimo. Letermovir meets primary goal of preventing cytomegalovirus infection in phase III clinical trial. DIA Daily 2016:4. [Ref.ID 100836]

Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Bakow B, Curran P, McKenney J, Tisch A, Reinert SE, Machan JT, Brandt LJ. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016:23 de agosto. [Ref.ID 100599]

Mayor S. “Impressive results” in stem cell treatment for multiple sclerosis. BMJ 2016;353:i3269. [Ref.ID 100429]

Castañeda-Sanabria J, Hjage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol 2016;72:737-46. [Ref.ID 100370]

Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel J-F, Jouet J-P, Clark E, Saccardi R, Tyndall A, Travis S, Farge D. Autologous hepatopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 2015;314:2524-34. [Ref.ID 99796]

Anónimo. Mycophenolate mofetil, mycophenolic acid: new pregnancy - prevention advice for women and men. Drug Safety Update 2015;9:3. [Ref.ID 99747]

Anónimo. FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. U.S. Food and Drug Administration 2015:22 de octubre. [Ref.ID 99573]

Gulmez SE, Larrey D, Pageux G-P, Bernuau J, Bissoli F, Horsmans Y, Thorburn D, McCormick PA, Stricker B, Toussi M, Lignot-Maleyran S, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Moore N. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol 2015;80:599-606. [Ref.ID 99554]

Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetnenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NH, Walewski J, for the AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853-62. [Ref.ID 99089]

Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers MED, Stevens-Ayers T, Jerome KR, Leisenring W. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 2015;162:1-10. [Ref.ID 98728]

Knoll G, Kokolo M, Mallick R, Beck A, Buenaventura C, Ducharme R, Barsoum R, Bernasconi C, Blydt-Hansen TD, Ekbergh H, Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba M, Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko S, Watson C, Fergusson DA. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014;349:g6679. [Ref.ID 98345]

The 3C Study Collaborative Group. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet 2014;384:1684-90. [Ref.ID 98323]

Thomas DL. A case for ribavirin to treat chronic hepatitis E. N Engl J Med 2014;370:1162-3. [Ref.ID 97312]

Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, Coilly A, Garrigue V, D'Alteroche L, Buchler M, Couzi L, Lebray P, Dharancy S, Minello A, Hourmant M, Roque-Afonso AM, Abravanel F, Pol S, Rostaing L, Mallet V. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014;370:1111-20. [Ref.ID 97310]

Anónimo. Évérolimus après transplantation hépatique. Prescrire 2013;33:730. [Ref.ID 96230]

Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Pariente A, Blin P, Bénichou J, Bégaud B. Choice of denominator in case population studies: event rates for registration for liver transplantation after exposure to NSIADs in the SALT study in France. Pharmacoepidemiol Drug Saf 2013;22:160-7. [Ref.ID 94867]